ArticleMolecular medicine reports2017
ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.International journal of molecular sciences · 2026Review
- Lysosomal Exocytosis of Olivacine on the Way to Explain Drug Resistance in Cancer Cells.International journal of molecular sciences · 2022Article
- Article
- Anticancer and Immunomodulatory Activities of a Novel Water-Soluble Derivative of Ellipticine.Molecules (Basel, Switzerland) · 2020Article
- Identification of Key Biomarkers in Bladder Cancer: Evidence from a Bioinformatics Analysis.Diagnostics (Basel, Switzerland) · 2020Article
- Sp1 contributes to radioresistance of cervical cancer through targeting G2/M cell cycle checkpoint CDK1.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ellipticine, an alkaloid isolated from Apocyanaceae plants, has been demonstrated to exhibit antitumor activity in several cancers. However, the effect and the mechanisms underlying its action have not been investigated in human bladder cancer cells. The aim of the present study was to investigate the effect and mechanism of ellipticine on the behavior of T‑24 bladder cancer cells. T‑24 cells were treated with varying concentrations and durations of ellipticine. Cell viability was evaluated by Cell Counting Kit‑8 assay. Cell motility was analyzed by Transwell migration assay. Flow cytometry, reverse transcription‑quantitative polymerase chain reaction and western blot analyses were performed to detect the cell cycle and signaling pathways involved. The results demonstrated that ellipticine suppressed proliferation and inhibited the migration ability of T‑24 bladder cancer cells in a dose‑ and time‑dependent manner, and resulted in G2/M cell cycle arrest. The mechanism of this action was demonstrated to be due to ellipticine‑triggered activation of the ATM serine/threonine kinase pathway. These data therefore suggest that ellipticine may be effective towards treating human bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.